Cargando…

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation show a high response to EGFR-tyrosine kinase inhibitor (EGFR-TKI). Clinically, EGFR-positive NSCLC acquires several resistance mechanisms during EGFR-TKI treatment, such as the emergence of a secondary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshimura, Akihiro, Uchino, Junji, Tanimura, Keiko, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Takeda, Takayuki, Hiranuma, Osamu, Hasegawa, Isao, Kubota, Yutaka, Shiotsu, Shinsuke, Takumi, Chieko, Hiraoka, Noriya, Yamada, Tadaaki, Takayama, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200532/ https://www.ncbi.nlm.nih.gov/pubmed/30290647 http://dx.doi.org/10.1097/MD.0000000000012660

Ejemplares similares

Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study
por: Seto, Yurie, et al.
Publicado: (2021)

Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment
por: Uchino, Junji, et al.
Publicado: (2018)

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial
por: Nakao, Akira, et al.
Publicado: (2019)

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
por: Nakao, Akira, et al.
Publicado: (2020)

Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial
por: Iwasaku, Masahiro, et al.
Publicado: (2023)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report
por: Nishioka, Naoya, et al.
Publicado: (2018)

Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis
por: Tanimura, Keiko, et al.
Publicado: (2018)

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
por: Shiotsu, Shinsuke, et al.
Publicado: (2022)

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients
por: Imabayashi, Tatsuya, et al.
Publicado: (2019)

Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions
por: Imabayashi, Tatsuya, et al.
Publicado: (2019)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
por: Yamada, Tadaaki, et al.
Publicado: (2019)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Epidermal growth factor receptor in glioblastoma
por: Xu, Hongsheng, et al.
Publicado: (2017)

Tumor Neovascularization and Developments in Therapeutics
por: Katayama, Yuki, et al.
Publicado: (2019)

Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management
por: Takayuki, Nakano, et al.
Publicado: (2018)

Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor.
por: Mellon, J. K., et al.
Publicado: (1996)

Expression and localization of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor in the canine testis
por: TAMADA, Hiromichi, et al.
Publicado: (2015)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor in Pancreatic Cancer
por: Oliveira-Cunha, Melissa, et al.
Publicado: (2011)

Epidermal Growth Factor Receptors and Breast Cancer
por: Farndon, J. R., et al.
Publicado: (1989)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer
por: Sobani, Zain A, et al.
Publicado: (2016)

Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma.
por: Filipe, M. I., et al.
Publicado: (1995)

Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration
por: Maisel, Sabrina, et al.
Publicado: (2017)

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
por: Nishioka, Naoya, et al.
Publicado: (2019)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Evaluation of epidermal growth factor receptors in bladder tumours.
por: Berger, M. S., et al.
Publicado: (1987)

Allosteric regulation of the epidermal growth factor receptor kinase
Publicado: (1986)

The epidermal growth factor receptor family in breast cancer
por: Koutras, Angelos K, et al.
Publicado: (2008)

Inhibiting Epidermal Growth Factor Receptor at a Distance
por: Sinclair, Julie K.-L., et al.
Publicado: (2014)

The epidermal growth factor receptor (EGRF) in lung cancer
por: Carcereny, Enric, et al.
Publicado: (2015)

Assessment of epidermal growth factor receptor status in glioblastomas
por: Zhu, Hui-Jun, et al.
Publicado: (2013)

Epidermal growth factor receptor function in the human urothelium
por: Wasén, C., et al.
Publicado: (2018)

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors
por: Uprety, Dipesh, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Expression in the Corneal Epithelium
por: Peterson, Joanne L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mm1etvoj34bh6kedl99grfpe5u